Dissecting Tumour MicroenvirOnment in Solid Paediatric Tumour to Improve Adoptive Cell The
Pediatric solid tumors exhibit a low mutational burden, limited availability of neoantigens, and poor infiltration of tumor-infiltrating lymphocytes (TILs) within the tumor microenvironment (TME), characteristics that reduce the effectiveness of immunotherapies in children. However, pediatric tumors express a subgroup
| Condition(s) | Pediatric Solid Tumors |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Summary | Pediatric solid tumors exhibit a low mutational burden, limited availability of neoantigens, and poor infiltration of tumor-infiltrating lymphocytes (TILs) within the tumor microenvironment (TME), characteristics that reduce the effectiveness of immunotherapies in children. However, pediatric tumors express a subgroup of antigens that can be exploited as targets. Stimulating the T lymphocyte response against these antigens could overcome immunosuppressive barriers. The adoption of therapies based on cytotoxic T lymphocytes (CTLs) represents a promising strategy. A total of 42 neoplasms were analyzed, including: 8 neuroblastomas, 7 sarcomas, 4 nephroblastomas, 1 renal carcinoma, 2 rhabdomyosarcomas, 5 lymphomas, 2 ovarian carcinomas, 4 teratomas, 2 thyroid tumors, and 7 other rare tumors. P |
| Who can participate | Inclusion Criteria: * pediatric patients 0-18 years * affected by solid tumors Exclusion Criteria: * patients over 18 * non-solid malignancies |
| Ages | 1 Day to 18 Years |
| Sex | All |
| Lead sponsor | Fondazione IRCCS Policlinico San Matteo di Pavia |
| Locations | Pavia, Pavia, Italy |
| Start date | 2023-01-19 |
| NCT ID | NCT07240207 |
| Official listing | https://clinicaltrials.gov/study/NCT07240207 |